僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Briakinumab （ABT-874） is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis